Resource Summary Report

Generated by RRID on Sep 1, 2026

NB4

RRID:CVCL_0005
Type: Cell Line

Proper Citation

RRID:CVCL_0005

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0005

Proper Citation: RRID:CVCL_0005

Description: Cell line NB4 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Acute promyelocytic leukemia with PML-RARA

Defining Citation: PMID:1453773, PMID:1995093, PMID:7630193, PMID:9737686, PMID:11704857, PMID:12353268, PMID:14504097, PMID:15843827, PMID:16408098, PMID:16957166, PMID:22460905, PMID:23325432, PMID:23955599, PMID:25877200, PMID:25894527, PMID:25984343, PMID:26589293, PMID:27397505, PMID:30285677, PMID:30629668, PMID:30894373, PMID:31068700, PMID:31160637, PMID:35839778, PMID:36982453

Comments: Population: Caucasian., Part of: LL-100 blood cancer cell line panel., Part of: Human Protein Atlas, Cell Atlas panel., Part of: ENCODE project common cell types; tier 3., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Patented cell line.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NB4

Synonyms: NB-4, NB.4

Cross References: BTO:BTO_0002136, CLO:CLO_0007947, EFO:EFO_0002798, MCCL:MCC:0000350, CLDB:cl3643, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-

7722, BioGRID_ORCS_Cell_line:212, BioSample:SAMN03470835, BioSample:SAMN10988571, cancercelllines:CVCL_0005, Cell_Model_Passport:SIDM00428, ChEMBL-Cells:CHEMBL3308423, ChEMBL-Targets:CHEMBL614188, CLS:300299, Cosmic:787463, Cosmic:850391, Cosmic:922661, Cosmic:924050, Cosmic:975285, Cosmic:981582, Cosmic:996313, Cosmic:1012107, Cosmic:1037664, Cosmic:1070692, Cosmic:1078721, Cosmic:1089522, Cosmic:1127257, Cosmic:1181601, Cosmic:1523826, Cosmic:1524838, Cosmic:1601063, Cosmic:1604862, Cosmic:1779130, Cosmic:2036677, Cosmic:2089653, Cosmic:2131548, Cosmic:2306227, Cosmic:2579202, Cosmic-CLP:1323913, DepMap:ACH-000294, DSMZ:ACC-207, DSMZCellDive:ACC-207, EGA:EGAS00001000978, ENCODE:ENCBS032SIL, ENCODE:ENCBS259AAA, ENCODE:ENCBS390ENC, GDSC:1323913, GEO:GSM236798, GEO:GSM236834, GEO:GSM472929, GEO:GSM510512, GEO:GSM510513, GEO:GSM749716, GEO:GSM887349, GEO:GSM888426, GEO:GSM945252, GEO:GSM945275, GEO:GSM1022643, GEO:GSM1374696, GEO:GSM1374697, GEO:GSM1446740, GEO:GSM1670151, GEO:GSM7701453, GEO:GSM7701458, IARC_TP53:21530, IARC_TP53:21705, LiGeA:CCLE_910, LINCS_LDP:LCL-1084, Lonza:749, NCBI_Iran:C515, PharmacoDB:NB4_990_2019, PRIDE:PXD000589, PRIDE:PXD001610, PRIDE:PXD030304, Progenetix:CVCL_0005, PubChem_Cell_line:CVCL_0005, Ubigene:YC-C122, Wikidata:Q54907527

ID: CVCL_0005

Record Creation Time: 20220427T220833+0000

Record Last Update: 20260829T234723+0000

Ratings and Alerts

No rating or validation information has been found for NB4.

No alerts have been found for NB4.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 53 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

van Eck van der Sluijs J, et al. (2026) Sialic acid cis-ligand dynamics modulate Siglec-7 and -9 function and affect Siglec-7/9 co-blockade to potentiate natural killer cell anti-tumor activity. Oncoimmunology, 15(1), 2649988.

Chen TQ, et al. (2026) RBM15B recognizes H3K79me2 to guide selective m6A-modification of mRNA and enhance oncoprotein translation in MLL-r leukemia. The EMBO

journal, 45(5), 1672.

Jones L, et al. (2026) A structure-based modeling approach identifies effective drug combinations for RAS-mutant acute myeloid leukemia. iScience, 29(8), 116875.

Uible EE, et al. (2026) Scaffolding-dependent CASP1 constrains excessive cell-intrinsic inflammatory signaling in leukemia. Cell chemical biology, 33(1), 59.

Pereira-Martins DA, et al. (2026) ??Np73 isoform defines a TP53-mutant-like poor-risk subgroup of acute myeloid leukemia. Cell reports. Medicine, 102540.

Su M, et al. (2026) FASN inactivation-induced progranulin (GRN) expression promotes lysosome-dependent cell death to suppress leukemogenesis. Cell reports, 45(3), 117042.

Leesang TE, et al. (2025) Retinoic acid and ascorbate synergize to suppress myeloid leukemia via TET2 activation. Cell reports, 44(10), 116379.

Peled A, et al. (2025) BKT300: A Novel Anti-Leukemic Small Molecule Targeting the Protein Regulator of Cytokinesis 1 (PRC1) Pathway. Research square.

Giovannini S, et al. (2025) Thioredoxin-interacting protein (TXNIP) is a substrate of the NEDD4-like E3 ubiquitin-protein ligase WWP1 in cellular redox state regulation of acute myeloid leukemia cells. Molecular oncology, 19(1), 133.

Shang K, et al. (2025) CD97-directed CAR-T cells with enhanced persistence eradicate acute myeloid leukemia in diverse xenograft models. Cell reports. Medicine, 6(6), 102148.

Venkataratnam Y, et al. (2025) Tunneling nanotubes between glioblastoma cells and T cells and hijack of mitochondria. Journal of neuro-oncology, 175(2), 571.

Balasundaram N, et al. (2025) A novel strategy to target metabolic dependencies in acute myeloid leukemia. Cell death & disease, 16(1), 792.

Biernacki MA, et al. (2025) SF3B1K700E Neoantigen Is a CD8+ T-cell Target Shared across Human Myeloid Neoplasms. Cancer immunology research, 13(9), 1391.

Chen Z, et al. (2025) YTHDF2 promotes ATP synthesis and immune evasion in B cell malignancies. Cell, 188(2), 331.

Chang YH, et al. (2024) SETDB1 suppresses NK cell-mediated immunosurveillance in acute myeloid leukemia with granulo-monocytic differentiation. Cell reports, 43(8), 114536.

Santana-Hern??ndez J, et al. (2024) Acute promyelocytic leukemia with PML/RARA (bcr1, bcr2 and bcr3) transcripts in a pediatric patient. Oncology letters, 27(3), 114.

Guo HZ, et al. (2024) A CD36-dependent non-canonical lipid metabolism program promotes immune escape and resistance to hypomethylating agent therapy in AML. Cell reports. Medicine, 5(6), 101592.

Pallavi R, et al. (2024) Caloric restriction leads to druggable LSD1-dependent cancer stem cells expansion. Nature communications, 15(1), 828.

Wang P, et al. (2024) Foretinib Is Effective in Acute Myeloid Leukemia by Inhibiting FLT3 and Overcoming Secondary Mutations That Drive Resistance to Quizartinib and Gilteritinib. Cancer research, 84(6), 905.

Han L, et al. (2023) METTL16 drives leukemogenesis and leukemia stem cell self-renewal by reprogramming BCAA metabolism. Cell stem cell, 30(1), 52.